Rationale of targeting protein cereblon as a potential strategy for cancer treatment

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F20%3A00013001" target="_blank" >RIV/00023736:_____/20:00013001 - isvavai.cz</a>
Result on the web
<a href="https://10.1358/dof.2020.45.5.3116300" target="_blank" >https://10.1358/dof.2020.45.5.3116300</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1358/dof.2020.45.5.3116300" target="_blank" >10.1358/dof.2020.45.5.3116300</a>

Result language
angličtina
Original language name
Rationale of targeting protein cereblon as a potential strategy for cancer treatment
Original language description
Thalidomide and its related agents (lenalidomide, pomalidomide, avadomide, iberdomide hydrochloride, CC-885, CC- 90009 and CC-92480) form the family of immunomodulatory or cereblon (CRBN) binding drugs (IMiDs) with anticancer and anti-inflammatory effects. CRBN acts as the substrate receptor of a cullin 4 really interesting new gene (RING) E3 ubiquitin ligase CRL4(CRBN). This E3 ubiquitin ligase ubiquitinates CRBN and other components of the CRL4(CRBN) complex in absence of lenalidomide. Presence of lenalidomide changes specificity of CRL4(CRBN), which then ubiquitinates 2 transcription factors, IKZF1 (Ikaros) and IKZF3 (Aiolos), and casein kinase 1alpha (CK1alpha) and marks them for degradation in proteasomes.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)